TWO-SAMPLE CONTINUAL REASSESSMENT METHOD

DOI10.1081/BIP-100100998MaRDI QIDQ4244513zbMATH OpenOpenAlexWikidataFDO

Authors John O'Quigley, Larry Zaiqian Shen, A. C. Gamst

Publication date 5 September 1999

Published in Journal of Biopharmaceutical Statistics (Search for Journal in Brave)

Full work available at URL https://doi.org/10.1081/bip-100100998

zbMATH Keywords

dose-toxicitypatient heterogeneityphase I clinical trials

Mathematics Subject Classification ID

Sequential statistical design (62L05) Applications of statistics to biology and medical sciences; meta analysis (62P10)

Recommendations

• A note on continual reassessment method
• A note on the robustness of the continual reassessment method
• A new design of the continual reassessment method
• Characterization of the likelihood continual reassessment method
• Consistency of continual reassessment method under model misspecification
• An improved estimation procedure in two-phase successive sampling
• Theoretical study of the continual reassessment method

Cited in

(18)

• A Bayesian adaptive design in cancer phase I trials using dose combinations in the presence of a baseline covariate
• Individualized dosing for multiple ordered groups of patients
• Adaptive clinical trial designs for phase I cancer studies
• Theoretical study of the continual reassessment method
• Continual reassessment method for ordered groups
• Patient‐Specific Dose Finding Based on Bivariate Outcomes and Covariates
• Efficiency of bridging between related dose finding studies
• Incorporating a patient dichotomous characteristic in cancer phase I clinical trials using escalation with overdose control
• Patient-specific dose finding in phase I clinical trials
• The Continual Reassessment Method for Multiple Toxicity Grades: A Bayesian Quasi‐Likelihood Approach
• Bayesian adaptive design of early-phase clinical trials for precision medicine based on cancer biomarkers
• Dimension of model parameter space and operating characteristics in adaptive dose-finding studies
• A design for phase I trials in completely or partially ordered groups
• Designs for phase I trials in ordered groups
• Dose individualization for phase I cancer trials with broadened eligibility
• Continual reassessment and related dose-finding designs
• Dose finding with escalation with overdose control (EWOC) in cancer clinical trials
• Design efficiency in dose finding studies

This page was built for publication: TWO-SAMPLE CONTINUAL REASSESSMENT METHOD

Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q4244513)